Abbott Laboratories Stock News

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Results from Johnson & Johnson NYSE: JNJ and Abbott Laboratories NYSE: ABT foreshadow good news for MedTech investors. Both companies outperformed on the top and bottom lines, driven by broad strength

Abbott Laboratories reported solid growth across all segments in its third-quarter results, excluding its COVID diagnostics portfolio. The company's medical devices business, which includes its Diabet

While there are many ways to position yourself in the market during this ambiguous juncture, one of the most straightforward approaches involves targeting blue-chip stocks to buy on the dip. By defini

CEO Robert Ford said more users of its glucose monitoring system were using the device while also taking new obesity drugs.

Robert Ford, Abbott chairman and CEO, joins 'Closing Bell Overtime' to talk Q3 earnings, the impact of weight loss drugs on their product and more.

Abbott (ABT) reports solid underlying base business performance in the third quarter of 2023.

Geopolitical Conflicts in Middle-East in Focus.

Abbott Laboratories (NYSE:ABT) shares rose after the healthcare technology company posted a third quarter earnings beat and provided strong full-year guidance. While revenue decreased 2.8% year-over-y

Abbott (ABT) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.10 per share. This compares to earnings of $1.15 per share a year ago.

Abbott Laboratories NYSE: ABT share price has trended lower for nearly 2 years, but that trend is over. The impact of COVID on sales and the post-COVID letdown were cause enough for the market to sell

Abbott stock rose moderately Wednesday after the company beat third-quarter expectations and raised the midpoint of its earnings view.

Healthcare-products firm Abbott beat third-quarter estimates despite a drop in sales of Covid-19 testing kits. It raised the midpoint of earnings guidance for the year.

Abbott Laboratories shares ABT, -0.04% climbed 2.5% premarket on Wednesday after the healthcare products company posted a better-than-expected third-quarter profit and raised its earnings guidance for

Abbott Laboratories on Wednesday tightened its profit forecast for the year after beating estimates for third-quarter earnings due to strong demand for its medical devices and diagnostics products.